For policy analysis, the most common measure of effectiveness is the QALY, making the units of the corresponding marginal cost-effectiveness ratio "additional dollars spent per QALY gained" However, the marginal cost-effectiveness ratio has been criticized because older patients or patients with life-limiting comorbidities have a smaller potential gain in survival from a treatment and therefore have a higher (less advantageous) cost-effectiveness ratio.